PHARMATHENE kurslich bald ne Hot-Stock

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

   SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
   Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
   Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection

In addition, pursuant to a final judgment issued May 31, 2012 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246®, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246®. For more information about PharmAthene, please visit www.PharmAthene.com.

im Sinne::Kopp in Nacken lassen sacken lassen zischen noch nen Frischen
die nehmen wir uns zur Brust..::watch...:::ENTER:::
buran

X-DAX 7.360 +0,36% Dow 13.610 +0,25%
  L-TecDAX       829    +1,00%      Euro    1,3028§+0,08%
__________________________________________

....>> ENTER <<

http://www.ariva.de/news/...rd-Quarter-2012-Financial-Results-4329441
GrB

                 100          §
  16:30:25§1,17 $
                 100          §
  16:30:25§1,175 $
                 100          §
  16:30:25§1,175 $
                 100          §
  16:30:25§1,175 $
                 100          §
  16:28:20§1,18 $
                 100          §
  16:26:42§1,18 $
                 200          §
  16:25:42§1,175 $
                 100          §
  16:21:37§1,18 $
                 100          §
  16:21:37§1,179 $
                 100          §
  16:10:11§1,179 $
                 100          §
  16:01:31§1,18 $
                 200          §
  16:01:30§1,1701 $
                 900          §
  16:01:30§1,17 $
                 500          §
  16:01:30§1,175 $
                 100          §
  16:01:24§1,17 $
               1.897          §
  16:00:46§1,18 $
                 100          §
  16:00:42§1,18 $
                 500          §
  16:00:42§1,1799 $
               1.000          §
  16:00:42§1,18 $
                 300          §
  16:00:42§1,1799 $
               1.200          §
  15:57:44§1,18 $
                 100          §
  15:44:39§1,1799 $
               1.000          §
  15:40:42§1,18 $
                 100          §
  15:40:30§1,18 $
                 100          §
  15:40:30§1,1701 $
               1.200          §
  15:40:30§1,17 $
               1.200          §
  15:40:29§1,1701 $
                 400          §
  15:40:29§1,17 $
                 400          §
  15:40:25§1,18 $
                 100          §
  15:40:25§1,17 $
                 400§
15:37:40 1,18 $
               4.100          §
  15:32:26§1,18 $
          §100

http://www.ariva.de/news/...Litigation-With-SIGA-Technologies-4401325 GrB

http://www.ariva.de/news/...ction-Of-Recombinant-Bioscavenger-4403674 GrB

190.967 shares sind getickert worden ..TH::1,30  ..Pott +13,39% ..sehr gute Leistung

At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 201315:35 17.01.13


PR Newswire

ANNAPOLIS, Md., Jan. 17, 2013

ANNAPOLIS, Md., Jan. 17, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Noble Financial Capital Markets Ninth Annual Equity Conference on Tuesday, January 22, 2013 at 9:30 a.m. ET in Room 1 at the Hard Rock Hotel, Hollywood, Florida.

Mr. Richman and Linda Chang, Senior Vice President and Chief Financial Officer, will also be available to participate in one-on-one meetings at the conference.

Event: Noble Financial Capital Markets 9th Annual Equity Conference      

Date:   Tuesday, January 22, 2013

Place: Hollywood, Florida; Hard Rock Hotel; Room 1

Time:  9:30 a.m. ET

SOURCE PharmAthene, Inc.


Quelle: PR Newswire

80.392 shares den Ticker durchflogen ..SK 1,30 in Dollar ..buran und MfG

TH (Tageshoch) 1,30USD ..soviel Zeit muss sein ..die da jedoch kurslich künftig nicht mehr bleiben dürfte ..gutes Omen ..buran

1,29 $ +1,57% +0,02 $

In Euro: 0,9687 € | AMEX

:::::PHARMATHENE

ät jibt nur ein Rudi Völlaaaaaaaaaaaaa ulla ulla oleeeeeeeeeeeeee

1,439 $ +4,27% +0,059 $ In Euro: 1,1080 € | AMEX, 20:32 buran

spread 3,93% / RT / GrB

http://www.ariva.de/news/...ts-Year-End-2012-Financial-And-Op-4465443 GrB

letzter Stand der Dinge
Datum Erster Hoch Tief Schluss     Stücke Volumen
26.03.13 1,76 1,77 1,68  1,75 $ 213.911 350 T
GrB

Zeit  Kurs  Stück  
15:48:38 1,61 $  500  
15:48:32 1,61 $  2.000  
15:48:05 1,65 $  100  
15:48:05 1,65 $  100  
15:48:05 1,65 $  100  
15:48:05 1,65 $  100  
15:48:05 1,65 $  100  
15:48:05 1,65 $  2.000  
15:48:05 1,66 $  100  
15:48:05 1,66 $  100  
15:48:05 1,65 $  300  
15:48:05 1,65 $  100  
15:46:29 1,6699 $  100  
15:46:29 1,6699 $  300  
15:40:05 1,66 $  500  
15:37:23 1,68 $  2.500  
15:30:17 1,74 $   400  
15:30:17 1,73 $  100  
15:30:17 1,70 $  100  
15:30:17 1,69 $  400  
15:30:01 1,69 $  100  
15:30:00 1,65 $  1.000

Franz Jäger Berlin ganz einfache Sache ..der Chart iss HAMMER ..und der Preis ist heiss::: Kauf: 1,60 $ Wartestücke: 544 spread: 1,91% ,GrB and good luck

Betreffzeile: die 1,58 $ somit heutiger 16er EK ..das sind 1,2058 € SHARP

buran

http://www.ariva.de/news/...harmAthene-s-Recombinant-Bioscave-4500488 GrB

was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical agents. PharmAthene's lead product development programs include:

SparVax® - next generation recombinant protective antigen (rPA) anthrax vaccine
Recombinant BChE- novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
Valortim® - fully human monoclonal antibody for the prevention and treatment of anthrax infection
In addition, pursuant to a final judgment issued May 31, 2012 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits (as defined in the Court's final judgment) over 10 years from all sales of SIGA Technologies' Arestvyr™ (formerly called ST-246®), a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of Arestvyr™.  Both parties have appealed aspects of this ruling to the Delaware Supreme Court.   A decision from the high court is expected in the second quarter of 2013.  For more information about PharmAthene, please visit www.PharmAthene.com.http://www.ariva.de/news/...nant-Bioscave-4500488

Buch

Zeit  Kurs  Stück  
15:50:09 1,62 $  100  
15:30:00 1,64 $  1.620

GrB

Betreffzeile: bid / ask ...hier:: ask:: 1,61 $ Stücke: 7 spread: 0,62%

nie gesehen ;-))

http://www.ariva.de/news/...-First-Quarter-2013-Financial-And-4524549 GrB